Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

Purpose: mRNA has broad therapeutic potential for vaccination, protein replacement, and gene editing, but its clinical translation is limited by the need for improved intracellular delivery systems. mRNA is much larger than siRNA or ASOs (~300–5,000 kDa, ~1–15 kb vs ~14 kDa and 4–10 kDa, respectively), making delivery more challenging. This review addresses the gap between mRNA's therapeutic promise and the delivery barriers that still restrict its broad application. ---

Hypothesis: The review’s central thesis is: if mRNA is engineered for stability/translatability and encapsulated in optimized non-viral delivery systems (LNPs, polymers, dendrimers, CPPs), then therapeutic mRNA can be effectively delivered for protein replacement, gene editing, and vaccination. Continued advances in biomaterials and formulation will overcome current delivery bottlenecks. ---

Aims: - Discuss challenges for clinical translation of mRNA-based therapeutics, emphasizing extracellular and intracellular barriers. - Review recent advances in biomaterials and delivery strategies for mRNA. - Provide an overview of mRNA applications in protein therapy, gene editing, and vaccination. - Summarize clinical development of mRNA vaccines and gene-editing therapeutics. ---

Delivery system: Payload: mRNA (conventional non-amplifying mRNA and self-amplifying mRNA/replicon), sgRNA, Cas9 mRNA, ZFN mRNA, neoantigens, tumor-associated antigens, therapeutic proteins (EPO, CFTR, factor IX, VEGF-A, etc.). Delivery vehicles: - Lipid nanoparticles (LNPs): ionizable/cationic lipids, helper lipids (DOPE, DSPC), cholesterol, PEG-lipid. Examples: MC3 (DLin-MC3-DMA), C12-200, LP-01, lipid 5, cKK-E12/MD1, OF-02, OF-Deg-Lin, ATX-100, ZA3-EP10 (ZALs). - Polymers: PEI (low MW, fatty-chain modified), poly(glycoamidoamine)s (Tar3C10), poly(β-amino esters) (PBAEs), hyperbranched PBAEs, OM-PBAEs, polymethacrylates, polyaspartamides, poly(acrylic acid) amides, charge-altering releasable transporters (CARTs), amino polyesters (APEs). - Dendrimers: PAMAM, polypropylenimine, fatty-chain modified PAMAM. - Cell-penetrating peptides (CPPs): RALA, Xentry-protamine. - Other: zwitterionic amino lipids (ZALs), virus-like particles (VLPs) coated with CPPs, Zr-MOF, mRNA nanoparticles via rolling circle transcription. - Protamine complexes: RNActive vaccine platform (CureVac). Targeting/tissue selectivity: Liver (via ApoE-dependent uptake), spleen (OF-Deg-Lin), lung endothelium, antigen-presenting cells (OM-PBAEs), dendritic cells (GALA-peptide polyplexes), lymph nodes. Administration routes: Systemic (IV), local (intramyocardial, intradermal, intramuscular, intratracheal, intranasal, intratumoral, intranodal, subcutaneous, intraperitoneal). ---

Approach: Narrative review of preclinical and clinical literature. Model systems discussed include: - In vitro: Various cell lines for transfection and protein expression. - In vivo: Mice, rabbits, pigs, non-human primates (NHPs) for protein replacement, gene editing, and vaccination. - Disease context: Hemophilia B, cystic fibrosis, myocardial infarction, hereditary tyrosinemia, ornithine transcarbamylase deficiency (OTCD), methylmalonic acidemia/aciduria (MMA), acute intermittent porphyria, cancer, infectious diseases (Zika, influenza, Ebola, HIV, rabies, CMV). - Clinical trials: Phase I/II/III trials of mRNA vaccines (CureVac, BioNTech, Moderna) and gene-editing therapeutics (CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Sangamo). ---

Key methods: Techniques and endpoints highlighted across cited studies: - Protein expression (EPO, luciferase, factor IX, CFTR) measured by ELISA, luminescence, or functional assays. - Indel frequency for CRISPR-Cas9 gene editing (e.g., PCSK9, Ttr). - Serum transthyretin levels for Ttr editing. - Antibody titers and neutralizing antibody assays for vaccines. - T cell activation and cytokine secretion assays (IFN-γ, granzyme). - Biodistribution and tissue-specific expression (liver, spleen, lung, heart). - Biodegradability and clearance studies (e.g., lipid clearance half-life). - Tumor growth inhibition and survival in cancer models. ---

Key results: - Protein expression half-life: Modified mRNA protein production half-life ranges from ~50 h in vitro to 7–30 h in vivo, depending on route. Circular RNAs provide up to 3-fold increase in half-life in vitro. - Liver expression: LNPs with lipid 5 achieved hEPO expression at doses as low as 0.01 mg/kg in NHPs, with peak expression at 6–12 h and sustained for over a month with weekly dosing. - Gene editing: LNP-mediated co-delivery of Cas9 mRNA and sgRNA achieved >80% indels for PCSK9 and >97% reduction in serum transthyretin for at least 12 months after a single dose. - Vaccines: mRNA-1647 (Moderna CMV vaccine) combines six mRNAs encoding different viral proteins. Zika mRNA vaccines produced virus-neutralizing antibodies after single or two low-dose vaccinations in mice, rabbits, and NHPs. - Polymer delivery: PBAE-mediated in vitro mRNA transfection was ~6-fold higher in the absence of serum proteins than in their presence. - Targeting: OF-Deg-Lin promoted spleen-selective protein expression; OF-02 promoted liver expression. APEs showed tissue-selective mRNA delivery based on core structure. - Biodegradability: LP-01 and lipid 5 cleared from liver rapidly (t₁/₂ ~6 h) compared to DLin-MC3-DMA (t₁/₂ > 50 h). ---

Interpretation: The authors conclude that mRNA therapeutics have gained significant momentum since the first proof-of-concept in 1978, with clinical efforts focused largely on vaccination. mRNA also has strong potential for local and systemic protein replacement and ex vivo/in vivo gene editing. Broad application is still limited by the need for improved delivery systems, but continued advances in mRNA nanoformulation using diverse materials will ultimately enable mRNA-based treatment of a wide range of diseases. ---

Limitations: - Delivery remains the major barrier: Intracellular delivery of mRNA is more challenging than siRNA or ASOs due to its larger size. - Endosomal escape is inefficient: Only ~1–2% of LNPs may evade degradation; the proton sponge hypothesis is incomplete, and mechanisms are complex. - Liver/spleen accumulation: MPS uptake limits delivery to other organs; targeting beyond liver/spleen is challenging. - Repeat dosing needed: Sustained protein levels require repeated administration due to transient mRNA expression. - Immunogenicity is double-edged: Innate immune activation can enhance vaccines but may degrade mRNA and reduce antigen expression; type I IFN effects are debated. - SAM vaccine limitations: Large replicon size (~10 kb), intolerance to nucleotide modifications, and potential host response to unrelated proteins. - Gene editing challenges: Off-target effects, low HDR efficiency, immune response to Cas9, large deletions/rearrangements, and p53 activation. - Polymer limitations: Polydispersity, clearance/biodegradation challenges for high-MW polymers, and limited clinical advancement compared to LNPs. - Dendrimer toxicity: Enzymatic biodegradation may be hindered by steric factors, leading to accumulation/toxicity. - Targeting ligand masking: Protein corona can mask targeting ligands and reduce active targeting efficacy. - As a review: Not a systematic review or meta-analysis; no primary data.